Neurodegenerative Disease Treatment Market, Global Outlook and Forecast 2022-2028

January 2022 | 62 pages | ID: N82A2A6D38C8EN
Market Monitor Global

Abstracts

Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.

This report contains market size and forecasts of Neurodegenerative Disease Treatment in Global, including the following market information:

Global Neurodegenerative Disease Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Neurodegenerative Disease Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Neurotransmitter Agents Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Neurodegenerative Disease Treatment include Allergan plc, Bayer AG, F. Hoffmann La-Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer, Inc. and Sanofi and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neurodegenerative Disease Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Neurodegenerative Disease Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Neurodegenerative Disease Treatment Market Segment Percentages, by Type, 2021 (%)

• Neurotransmitter Agents
• Neuroprotective Agents
• Biologics
• Others

Global Neurodegenerative Disease Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Neurodegenerative Disease Treatment Market Segment Percentages, by Application, 2021 (%)

• Multiple Sclerosis [MS]
• Alzheimer’s Disease
• Parkinson's Disease
• Acute Migraine
• Autism
• Narcolepsy
• Amyotrophic Lateral Sclerosis [ALS]
• Attention Deficit Hyperactivity Disorder [ADHD]
• Spinal Muscular Atrophy
• Huntington's Disease

Global Neurodegenerative Disease Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Neurodegenerative Disease Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Neurodegenerative Disease Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Neurodegenerative Disease Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Allergan plc
• Bayer AG
• F. Hoffmann La-Roche Ltd.
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck KGaA
• Novartis AG
• Pfizer, Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Neurodegenerative Disease Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Neurodegenerative Disease Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL NEURODEGENERATIVE DISEASE TREATMENT OVERALL MARKET SIZE

2.1 Global Neurodegenerative Disease Treatment Market Size: 2021 VS 2028
2.2 Global Neurodegenerative Disease Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Neurodegenerative Disease Treatment Players in Global Market
3.2 Top Global Neurodegenerative Disease Treatment Companies Ranked by Revenue
3.3 Global Neurodegenerative Disease Treatment Revenue by Companies
3.4 Top 3 and Top 5 Neurodegenerative Disease Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Neurodegenerative Disease Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Neurodegenerative Disease Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Neurodegenerative Disease Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Neurodegenerative Disease Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Neurodegenerative Disease Treatment Market Size Markets, 2021 & 2028
  4.1.2 Neurotransmitter Agents
  4.1.3 Neuroprotective Agents
  4.1.4 Biologics
  4.1.5 Others
4.2 By Type - Global Neurodegenerative Disease Treatment Revenue & Forecasts
  4.2.1 By Type - Global Neurodegenerative Disease Treatment Revenue, 2017-2022
  4.2.2 By Type - Global Neurodegenerative Disease Treatment Revenue, 2023-2028
  4.2.3 By Type - Global Neurodegenerative Disease Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Neurodegenerative Disease Treatment Market Size, 2021 & 2028
  5.1.2 Multiple Sclerosis [MS]
  5.1.3 Alzheimer’s Disease
  5.1.4 Parkinson's Disease
  5.1.5 Acute Migraine
  5.1.6 Autism
  5.1.7 Narcolepsy
  5.1.8 Amyotrophic Lateral Sclerosis [ALS]
  5.1.9 Attention Deficit Hyperactivity Disorder [ADHD]
  5.1.10 Spinal Muscular Atrophy
  5.1.11 Huntington's Disease
5.2 By Application - Global Neurodegenerative Disease Treatment Revenue & Forecasts
  5.2.1 By Application - Global Neurodegenerative Disease Treatment Revenue, 2017-2022
  5.2.2 By Application - Global Neurodegenerative Disease Treatment Revenue, 2023-2028
  5.2.3 By Application - Global Neurodegenerative Disease Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Neurodegenerative Disease Treatment Market Size, 2021 & 2028
6.2 By Region - Global Neurodegenerative Disease Treatment Revenue & Forecasts
  6.2.1 By Region - Global Neurodegenerative Disease Treatment Revenue, 2017-2022
  6.2.2 By Region - Global Neurodegenerative Disease Treatment Revenue, 2023-2028
  6.2.3 By Region - Global Neurodegenerative Disease Treatment Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Neurodegenerative Disease Treatment Revenue, 2017-2028
  6.3.2 US Neurodegenerative Disease Treatment Market Size, 2017-2028
  6.3.3 Canada Neurodegenerative Disease Treatment Market Size, 2017-2028
  6.3.4 Mexico Neurodegenerative Disease Treatment Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Neurodegenerative Disease Treatment Revenue, 2017-2028
  6.4.2 Germany Neurodegenerative Disease Treatment Market Size, 2017-2028
  6.4.3 France Neurodegenerative Disease Treatment Market Size, 2017-2028
  6.4.4 U.K. Neurodegenerative Disease Treatment Market Size, 2017-2028
  6.4.5 Italy Neurodegenerative Disease Treatment Market Size, 2017-2028
  6.4.6 Russia Neurodegenerative Disease Treatment Market Size, 2017-2028
  6.4.7 Nordic Countries Neurodegenerative Disease Treatment Market Size, 2017-2028
  6.4.8 Benelux Neurodegenerative Disease Treatment Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Neurodegenerative Disease Treatment Revenue, 2017-2028
  6.5.2 China Neurodegenerative Disease Treatment Market Size, 2017-2028
  6.5.3 Japan Neurodegenerative Disease Treatment Market Size, 2017-2028
  6.5.4 South Korea Neurodegenerative Disease Treatment Market Size, 2017-2028
  6.5.5 Southeast Asia Neurodegenerative Disease Treatment Market Size, 2017-2028
  6.5.6 India Neurodegenerative Disease Treatment Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Neurodegenerative Disease Treatment Revenue, 2017-2028
  6.6.2 Brazil Neurodegenerative Disease Treatment Market Size, 2017-2028
  6.6.3 Argentina Neurodegenerative Disease Treatment Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Neurodegenerative Disease Treatment Revenue, 2017-2028
  6.7.2 Turkey Neurodegenerative Disease Treatment Market Size, 2017-2028
  6.7.3 Israel Neurodegenerative Disease Treatment Market Size, 2017-2028
  6.7.4 Saudi Arabia Neurodegenerative Disease Treatment Market Size, 2017-2028
  6.7.5 UAE Neurodegenerative Disease Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Allergan plc
  7.1.1 Allergan plc Corporate Summary
  7.1.2 Allergan plc Business Overview
  7.1.3 Allergan plc Neurodegenerative Disease Treatment Major Product Offerings
  7.1.4 Allergan plc Neurodegenerative Disease Treatment Revenue in Global Market (2017-2022)
  7.1.5 Allergan plc Key News
7.2 Bayer AG
  7.2.1 Bayer AG Corporate Summary
  7.2.2 Bayer AG Business Overview
  7.2.3 Bayer AG Neurodegenerative Disease Treatment Major Product Offerings
  7.2.4 Bayer AG Neurodegenerative Disease Treatment Revenue in Global Market (2017-2022)
  7.2.5 Bayer AG Key News
7.3 F. Hoffmann La-Roche Ltd.
  7.3.1 F. Hoffmann La-Roche Ltd. Corporate Summary
  7.3.2 F. Hoffmann La-Roche Ltd. Business Overview
  7.3.3 F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Major Product Offerings
  7.3.4 F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Revenue in Global Market (2017-2022)
  7.3.5 F. Hoffmann La-Roche Ltd. Key News
7.4 GlaxoSmithKline plc
  7.4.1 GlaxoSmithKline plc Corporate Summary
  7.4.2 GlaxoSmithKline plc Business Overview
  7.4.3 GlaxoSmithKline plc Neurodegenerative Disease Treatment Major Product Offerings
  7.4.4 GlaxoSmithKline plc Neurodegenerative Disease Treatment Revenue in Global Market (2017-2022)
  7.4.5 GlaxoSmithKline plc Key News
7.5 Johnson & Johnson
  7.5.1 Johnson & Johnson Corporate Summary
  7.5.2 Johnson & Johnson Business Overview
  7.5.3 Johnson & Johnson Neurodegenerative Disease Treatment Major Product Offerings
  7.5.4 Johnson & Johnson Neurodegenerative Disease Treatment Revenue in Global Market (2017-2022)
  7.5.5 Johnson & Johnson Key News
7.6 Merck KGaA
  7.6.1 Merck KGaA Corporate Summary
  7.6.2 Merck KGaA Business Overview
  7.6.3 Merck KGaA Neurodegenerative Disease Treatment Major Product Offerings
  7.6.4 Merck KGaA Neurodegenerative Disease Treatment Revenue in Global Market (2017-2022)
  7.6.5 Merck KGaA Key News
7.7 Novartis AG
  7.7.1 Novartis AG Corporate Summary
  7.7.2 Novartis AG Business Overview
  7.7.3 Novartis AG Neurodegenerative Disease Treatment Major Product Offerings
  7.7.4 Novartis AG Neurodegenerative Disease Treatment Revenue in Global Market (2017-2022)
  7.7.5 Novartis AG Key News
7.8 Pfizer, Inc.
  7.8.1 Pfizer, Inc. Corporate Summary
  7.8.2 Pfizer, Inc. Business Overview
  7.8.3 Pfizer, Inc. Neurodegenerative Disease Treatment Major Product Offerings
  7.8.4 Pfizer, Inc. Neurodegenerative Disease Treatment Revenue in Global Market (2017-2022)
  7.8.5 Pfizer, Inc. Key News
7.9 Sanofi
  7.9.1 Sanofi Corporate Summary
  7.9.2 Sanofi Business Overview
  7.9.3 Sanofi Neurodegenerative Disease Treatment Major Product Offerings
  7.9.4 Sanofi Neurodegenerative Disease Treatment Revenue in Global Market (2017-2022)
  7.9.5 Sanofi Key News
7.10 Teva Pharmaceutical Industries Ltd.
  7.10.1 Teva Pharmaceutical Industries Ltd. Corporate Summary
  7.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
  7.10.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Major Product Offerings
  7.10.4 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Revenue in Global Market (2017-2022)
  7.10.5 Teva Pharmaceutical Industries Ltd. Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Neurodegenerative Disease Treatment Market Opportunities & Trends in Global Market
Table 2. Neurodegenerative Disease Treatment Market Drivers in Global Market
Table 3. Neurodegenerative Disease Treatment Market Restraints in Global Market
Table 4. Key Players of Neurodegenerative Disease Treatment in Global Market
Table 5. Top Neurodegenerative Disease Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Neurodegenerative Disease Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Neurodegenerative Disease Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Neurodegenerative Disease Treatment Product Type
Table 9. List of Global Tier 1 Neurodegenerative Disease Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neurodegenerative Disease Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Neurodegenerative Disease Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Neurodegenerative Disease Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Neurodegenerative Disease Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Neurodegenerative Disease Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Neurodegenerative Disease Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Neurodegenerative Disease Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Allergan plc Corporate Summary
Table 31. Allergan plc Neurodegenerative Disease Treatment Product Offerings
Table 32. Allergan plc Neurodegenerative Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Bayer AG Corporate Summary
Table 34. Bayer AG Neurodegenerative Disease Treatment Product Offerings
Table 35. Bayer AG Neurodegenerative Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 36. F. Hoffmann La-Roche Ltd. Corporate Summary
Table 37. F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Product Offerings
Table 38. F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 39. GlaxoSmithKline plc Corporate Summary
Table 40. GlaxoSmithKline plc Neurodegenerative Disease Treatment Product Offerings
Table 41. GlaxoSmithKline plc Neurodegenerative Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Johnson & Johnson Corporate Summary
Table 43. Johnson & Johnson Neurodegenerative Disease Treatment Product Offerings
Table 44. Johnson & Johnson Neurodegenerative Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Merck KGaA Corporate Summary
Table 46. Merck KGaA Neurodegenerative Disease Treatment Product Offerings
Table 47. Merck KGaA Neurodegenerative Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Novartis AG Corporate Summary
Table 49. Novartis AG Neurodegenerative Disease Treatment Product Offerings
Table 50. Novartis AG Neurodegenerative Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Pfizer, Inc. Corporate Summary
Table 52. Pfizer, Inc. Neurodegenerative Disease Treatment Product Offerings
Table 53. Pfizer, Inc. Neurodegenerative Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Sanofi Corporate Summary
Table 55. Sanofi Neurodegenerative Disease Treatment Product Offerings
Table 56. Sanofi Neurodegenerative Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 57. Teva Pharmaceutical Industries Ltd. Corporate Summary
Table 58. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Product Offerings
Table 59. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Neurodegenerative Disease Treatment Segment by Type in 2021
Figure 2. Neurodegenerative Disease Treatment Segment by Application in 2021
Figure 3. Global Neurodegenerative Disease Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Neurodegenerative Disease Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Neurodegenerative Disease Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Neurodegenerative Disease Treatment Revenue in 2021
Figure 8. By Type - Global Neurodegenerative Disease Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Neurodegenerative Disease Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Neurodegenerative Disease Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Neurodegenerative Disease Treatment Revenue Market Share, 2017-2028
Figure 12. US Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Neurodegenerative Disease Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Neurodegenerative Disease Treatment Revenue Market Share, 2017-2028
Figure 24. China Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Neurodegenerative Disease Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Neurodegenerative Disease Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Neurodegenerative Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Allergan plc Neurodegenerative Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bayer AG Neurodegenerative Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. GlaxoSmithKline plc Neurodegenerative Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Johnson & Johnson Neurodegenerative Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Merck KGaA Neurodegenerative Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Novartis AG Neurodegenerative Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Pfizer, Inc. Neurodegenerative Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Sanofi Neurodegenerative Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)